Antibiotic therapy, supportive treatment and management of immunomodulation inflammation response in community acquired pneumonia: review of recommendations
Antibiotic therapy, supportive treatment and management of immunomodulation inflammation response in community acquired pneumonia: review of recommendations
Authors
Marco Mantero
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milano
Paolo Tarsia
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milano
Andrea Gramegna
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milano
Sonia Henchi
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milano
Nicolò Vanoni
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milano
Marta Di Pasquale
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milano
Acute respiratory failure, Antibiotic therapy, Community acquired pneumonia, Duration of therapy, Inflammatory response
Abstract
Community-acquired pneumonia is a common and serious disease, with high rates of morbidity and mortality. Management and treatment of community-acquired pneumonia are described in three main documents: the 2007 American Thoracic Society guidelines, the 2011 European Respiratory Society guidelines, and the 2009 British Thoracic Society guidelines, updated by the NICE in 2015. Despite the validity of current guidelines in improving prognosis and management of patients with community-acquired pneumonia, not all recommendations have high levels of evidence and there are still some controversial issues. In particular, there are some areas of low evidence such as the efficacy of an antibiotic molecule or scheme in patients with same risk factors; duration of antibiotic treatment, supportive therapy for acute respiratory failure and immunomodulation molecules. This review will summarize the main recommendations with high level of evidence and discuss the recommendations with lower evidence, analyzing the studies published after the guidelines’ release.
Mantero M, Tarsia P, Gramegna A, Henchi S, Vanoni N, Di Pasquale M. Antibiotic therapy, supportive treatment and management of immunomodulation inflammation response in community acquired pneumonia: review of recommendations. Multidiscip Respir Med [Internet]. 2017 Jul. 17 [cited 2024 Jul. 4];12(1). Available from: https://mrmjournal.org/index.php/mrm/article/view/252
We are pleased to announce that we have implemented a new plugin for our journal, which will track citations from Scopus, Google Scholar, Crossref, and Europe PMC. This will allow authors to easily see how many times their work has been cited in these databases. Europe PMC also serves as a search engine and directly links to the work as indexed on PubMed and PubMedCentral, providing additional visibility. The plugin widget (see below) can be found at the bottom of each published work, and by clicking on the database symbols, authors can view the citation numbers.
